194 related articles for article (PubMed ID: 26054711)
1. Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome.
Counsilman CE; Jol-van der Zijde CM; Stevens J; Cransberg K; Bredius RG; Sukhai RN
Pediatr Nephrol; 2015 Aug; 30(8):1367-70. PubMed ID: 26054711
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of rituximab therapy against intractable steroid-resistant nephrotic syndrome.
Nakagawa T; Shiratori A; Kawaba Y; Kanda K; Tanaka R
Pediatr Int; 2016 Oct; 58(10):1003-1008. PubMed ID: 26865241
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of rituximab- and steroid-resistant nephrotic syndrome with leukocytapheresis.
Takakura M; Shimizu M; Mizuta M; Inoue N; Tasaki Y; Ohta K; Furuichi K; Wada T; Yachie A
J Clin Apher; 2018 Jun; 33(3):409-411. PubMed ID: 29341230
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature.
Van Horebeek I; Knops N; Van Dyck M; Levtchenko E; Mekahli D
Acta Clin Belg; 2017 Jun; 72(3):147-155. PubMed ID: 27409338
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
Huang J; Du J; Wang S; Xiao L; Zhao X
Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
[TBL] [Abstract][Full Text] [Related]
6. Crohn's disease following rituximab treatment in a patient with refractory nephrotic syndrome.
Morita K; Shibano T; Maekawa K; Hattori M; Hida N; Nakamura S; Takeshima Y
CEN Case Rep; 2019 Feb; 8(1):55-60. PubMed ID: 30251194
[TBL] [Abstract][Full Text] [Related]
7. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.
Guigonis V; Dallocchio A; Baudouin V; Dehennault M; Hachon-Le Camus C; Afanetti M; Groothoff J; Llanas B; Niaudet P; Nivet H; Raynaud N; Taque S; Ronco P; Bouissou F
Pediatr Nephrol; 2008 Aug; 23(8):1269-79. PubMed ID: 18465150
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of rituximab therapy in children with nephrotic syndrome: a 10-year experience from an Iranian pediatric hospital.
Bazargani B; Noparast Z; Khedmat L; Fahimi D; Esfahani ST; Moghtaderi M; Abbasi A; Afshin A; Mojtahedi SY
BMC Pediatr; 2022 Jan; 22(1):36. PubMed ID: 35022016
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of rituximab therapy in children with refractory nephrotic syndrome: a prospective observational study in Shanghai.
Sun L; Xu H; Shen Q; Cao Q; Rao J; Liu HM; Fang XY; Zhou LJ
World J Pediatr; 2014 Feb; 10(1):59-63. PubMed ID: 24464665
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
Kamei K; Ogura M; Sato M; Sako M; Iijima K; Ito S
Pediatr Nephrol; 2016 Jan; 31(1):89-95. PubMed ID: 26341251
[TBL] [Abstract][Full Text] [Related]
11. Cost analysis on the use of rituximab and calcineurin inhibitors in children and adolescents with steroid-dependent nephrotic syndrome.
Iorember F; Aviles D; Kallash M; Bamgbola O
Pediatr Nephrol; 2018 Feb; 33(2):261-267. PubMed ID: 28864927
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in The Management of Pediatric Steroid-Resistant Nephrotic Syndrome: A Systematic Review.
Jellouli M; Charfi R; Maalej B; Mahfoud A; Trabelsi S; Gargah T
J Pediatr; 2018 Jun; 197():191-197.e1. PubMed ID: 29680473
[TBL] [Abstract][Full Text] [Related]
13. Idiopathic nephrotic syndrome and rituximab: may we predict circulating B lymphocytes recovery?
Delbet JD; Leclerc G; Ulinski T
Pediatr Nephrol; 2019 Mar; 34(3):529-532. PubMed ID: 30542932
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.
Ahn YH; Kim SH; Han KH; Choi HJ; Cho H; Lee JW; Shin JI; Cho MH; Lee JH; Park YS; Ha IS; Cheong HI; Kim SY; Lee SJ; Kang HG
Medicine (Baltimore); 2018 Nov; 97(46):e13157. PubMed ID: 30431588
[TBL] [Abstract][Full Text] [Related]
15. Urinary excretion of sphingomyelinase phosphodiesterase acid-like 3b in children with intractable nephrotic syndrome.
Watanabe S; Tsugawa K; Tsuruga K; Imaizumi T; Tanaka H
Pediatr Int; 2017 Oct; 59(10):1112-1115. PubMed ID: 29081073
[TBL] [Abstract][Full Text] [Related]
16. Rituximab treatment for refractory steroid-resistant nephrotic syndrome.
Kamei K; Ishikura K
Pediatr Nephrol; 2016 Feb; 31(2):337-8. PubMed ID: 26386588
[No Abstract] [Full Text] [Related]
17. Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.
Ravani P; Bonanni A; Rossi R; Caridi G; Ghiggeri GM
Clin J Am Soc Nephrol; 2016 Apr; 11(4):710-20. PubMed ID: 26585985
[TBL] [Abstract][Full Text] [Related]
18. Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome.
Parmentier C; Delbet JD; Decramer S; Boyer O; Hogan J; Ulinski T
Pediatr Nephrol; 2020 Mar; 35(3):455-462. PubMed ID: 31705306
[TBL] [Abstract][Full Text] [Related]
19. Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome.
Fujinaga S; Sakuraya K; Yamada A; Urushihara Y; Ohtomo Y; Shimizu T
Pediatr Nephrol; 2015 Apr; 30(4):687-91. PubMed ID: 25576066
[TBL] [Abstract][Full Text] [Related]
20. Rituximab-induced serum sickness in a 6-year-old boy with steroid-dependent nephrotic syndrome.
Nakamura M; Kanda S; Yoshioka Y; Takahashi C; Owada K; Kajiho Y; Harita Y; Oka A
CEN Case Rep; 2020 May; 9(2):173-176. PubMed ID: 31970629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
